Individualized vancomycin dosing for NICU patients
Part of Infections clinical trials.
This study tests a personalized dosing approach for the antibiotic vancomycin given to patients in the neurological ICU. It aims to find the right dose for each patient to improve treatment and reduce side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are currently being treated in the neurological intensive care unit (NICU).
- You are 18 years old or older.
- You do not have significant kidney problems (like needing dialysis or a history of chronic kidney disease).
- You are not pregnant.
- Your height and weight are recorded in the hospital system.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a different way of giving vancomycin to children with sepsis to reduce the risk of kidney injury. It compares standard dosing to an approach that adjusts dose based on how the kidneys are working.
This study looks at how the antibiotic vancomycin moves through and acts in newborn babies. It may help doctors dose the medicine more safely and effectively for babies in intensive care.
This trial studies a better way to monitor and adjust vancomycin (an antibiotic) dosing in very young infants. It may help your baby get the right dose while reducing the risk of under- or over-dosing.
This study looks at giving vancomycin continuously in the ICU or orthopedics for the first time, to see if the dosing is done correctly. If you’re an adult receiving this treatment, the trial may help improve how safely and accurately vancomycin is managed.
This study asks NICUs to reduce the use of the antibiotic vancomycin. It's for hospital units that are part of certain networks and agree to follow the study plan.
This trial compares two ways of dosing vancomycin (an antibiotic) for serious MRSA infections by using different blood test targets. The goal is to see if the newer approach works at least as well as the standard one, while keeping patients safe.
Hear when a new Severe Infection trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.